Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 0.47 |
| ▸ | HTR6 | P50406 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320637 | 1.00 | MAPT (0.48) | MAPTALDH1A1LMNAAURKAAURKB | |
| SCHEMBL4322686 | 0.88 | AURKA (0.48) | MAPTALDH1A1LMNAAURKAAURKB | |
| SCHEMBL4322689 | 0.88 | AURKA (0.48) | MAPTALDH1A1LMNAAURKAAURKB | |
| SCHEMBL4309001 | 0.85 | AURKA (0.44) | MAPTALDH1A1LMNAAURKAAURKB | |
| SCHEMBL4309003 | 0.85 | AURKA (0.44) | MAPTALDH1A1LMNAAURKAAURKB | |
| SCHEMBL4313362 | 0.83 | FGFR1 (0.52) | MAPTAURKAAURKBFGFR1FLT1 | |
| SCHEMBL4313359 | 0.83 | FGFR1 (0.52) | MAPTAURKAAURKBFGFR1FLT1 | |
| SCHEMBL4316473 | 0.81 | MAPT (0.48) | MAPTALDH1A1LMNAAURKAAURKB | |
| SCHEMBL4322777 | 0.81 | MAPT (0.53) | MAPTALDH1A1LMNAAURKAAURKB | |
| SCHEMBL4316463 | 0.81 | MAPT (0.48) | MAPTALDH1A1LMNAAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | MAPT 4175/4885ALDH1A1 1250/4885LMNA 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.